• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 13 (7), 2017
  3. 667-676
  • Issues
    Online First Current Issue All Issues

International Journal of Pharmacology

Year: 2017 | Volume: 13 | Issue: 7 | Page No.: 667-676
DOI: 10.3923/ijp.2017.667.676

Facebook Twitter Reddit Linkedin E-mail
ASCI
Review Article

Advances in Designing and Developing Vaccines Against Zika Virus

Ashok Munjal
Department of Biochemistry and Genetics, Barkatullah University, Bhopal, Madhya Pradesh, India
LiveDNA: 91.12458

Rekha Khandia
Department of Biochemistry and Genetics, Barkatullah University, Bhopal, Madhya Pradesh, India
LiveDNA: 91.12456

Ruchi Tiwari
Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan, Mathura, Uttar Pradesh, India
LiveDNA: 91.10804

Sandip Chakraborty
Department of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry, R.K. Nagar, 799008 West Tripura, India
LiveDNA: 91.16289

Kumaragurubaran Karthik
Central University Laboratory, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, India
LiveDNA: 91.12455

Kuldeep Dhama
Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
LiveDNA: 91.4710

The recent outbreaks of Zika virus (ZIKV) infections has changed the ZIKV status from a very mild self-limiting febrile virus to a highly pathogenic virus causing visual impairment, autoimmune response against myelin layer and microcephaly in affected fetus. The serious social impact on society has drawn the attention of the researchers globally. The search for an effective vaccine against ZIKV is on the way. Several researches as well as commercial organizations are indulged in developing vaccine for prophylactic and treatment purposes. In the present review, various vaccine strategies have been described including inactivated, attenuated, DNA, subunit, recombinant viral vectored and nucleic acid based vaccines. The vaccines developed should be clinically tested in animal models, which are susceptible for ZIKV infection like Stat2-/- mice, A129 (IFNAR-/-) Mice, Swiss Jim Lambert (SJL) mice or Rhesus macaques. Efficacy of each vaccination strategy is required to be meticulously evaluated. The use of vaccinomics could also help to discover appropriate vaccine candidate to induce the effective immune response. DNA and subunit vaccines may not be that much beneficial in endemic areas due to poor immunogenic potential; however, by adjuvanting or using specific devise to deliver DNA vaccine construct, efficacy may be improved. Investigations exploring the cross reaction between the already existing immunity and immunity against newly developed vaccines would be of interest and useful for researchers. Further, researches should target whether vaccines and/or antibodies against ZIKV can induce Antibody Dependent Enhancement (ADE) resulting in subsequent enhancement of flavivirus infection. There are utmost requirements of sufficient resources in terms of infrastructure, funding, manpower, along with producing effective and safe ZIKV vaccine in commercial basis.
PDF Fulltext XML References Citation

How to cite this article

Ashok Munjal, Rekha Khandia, Ruchi Tiwari, Sandip Chakraborty, Kumaragurubaran Karthik and Kuldeep Dhama, 2017. Advances in Designing and Developing Vaccines Against Zika Virus. International Journal of Pharmacology, 13: 667-676.

DOI: 10.3923/ijp.2017.667.676

URL: https://scialert.net/abstract/?doi=ijp.2017.667.676

Leave a Comment


Your email address will not be published. Required fields are marked *

Article Trend



Total views 2936

References


  1. Lanciotti, R.S., O.L. Kosoy, J.J. Laven, J.O. Velez and A.J. Lambert et al., 2008. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerging Infect. Dis., 14: 1232-1239.
    CrossRefDirect Link

  2. Buathong, R., L. Hermann, B. Thaisomboonsuk, W. Rutvisuttinunt and C. Klungthong et al., 2015. Detection of Zika virus infection in Thailand, 2012-2014. Am. J. Trop. Med. Hyg., 93: 380-383.
    CrossRefDirect Link

  3. Oduyebo, T., E.R. Petersen, S.A. Rasmussen, P.S. Mead and D. Meaney-Delman et al., 2016. Update: Interim guidelines for health care providers caring for pregnant women and women of reproductive age with possible Zika virus exposure-United States, 2016. MMWR Morb. Mortal. Wkly. Rep., 65: 122-127.
    CrossRefDirect Link

  4. Berthet, N., E. Nakoune, B. Kamgang, B. Selekon and S.D. Declere et al., 2014. Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the central African republic. Vector-Borne Zoonotic Dis., 14: 862-865.
    CrossRefDirect Link

  5. Chang, C., K. Ortiz, A. Ansari and M.E. Gershwin, 2016. The Zika outbreak of the 21st century. J. Autoimmunity, 68: 1-13.
    CrossRefDirect Link

  6. Zanluca, C. and C.N.D. dos Santos, 2016. Zika virus-an overview. Microbes Infect., 18: 295-301.
    CrossRefDirect Link

  7. Bidet, K. and M.A. Garcia-Blanco, 2014. Flaviviral RNAs: Weapons and targets in the war between virus and host. Biochem. J., 462: 215-230.
    CrossRefDirect Link

  8. Faye, O., C.C.M. Freire, A. Iamarino, O. Faye and J.V.C. de Oliveira et al., 2014. Molecular evolution of Zika virus during its emergence in the 20th century. PloS Negl. Trop. Dis., Vol. 8.
    CrossRefDirect Link

  9. Musso, D., 2015. Zika virus transmission from French Polynesia to Brazil. Emerg. Infect. Dis., 21: 1887-1887.
    CrossRef

  10. Weaver, S.C., F. Costa, M.A. Garcia-Blanco, A.I. Ko and G.S. Ribeiro et al., 2016. Zika virus: History, emergence, biology and prospects for control. Antiviral Res., 130: 69-80.
    CrossRefDirect Link

  11. Weiskopf, D., D.J. Bangs, J. Sidney, R.V. Kolla and A.D. de Silva et al., 2015. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. USA., 112: 4256-4263.
    CrossRefPubMedDirect Link

  12. Swanstrom, J.A., J.A. Plante, K.S. Plante, E.F. Young and E. McGowan et al., 2016. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio, 7: e01123-16.
    CrossRefDirect Link

  13. Whiteman M.C., L. Li, J.A. Wicker, R.M. Kinney and C. Huang et al., 2010. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine, 28: 1075-1083.
    CrossRefPubMedDirect Link

  14. Awasthi, S., 2016. Zika virus: Prospects for the development of vaccine and antiviral agents. J. Antivir. Antiretrovir., 8: 61-63.
    CrossRefDirect Link

  15. Durbin, A.P., 2016. Vaccine development for Zika virus-timelines and strategies. Semin. Reprod. Med., 34: 299-304.
    CrossRefDirect Link

  16. Dudley, D.M., M.T. Aliota, E.L. Mohr, A.M. Weiler and G. Lehrer-Brey et al., 2016. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun., Vol. 7.
    CrossRefDirect Link

  17. Pawitwar, S.S., S. Dhar, S. Tiwari, C.R. Ojha and J. Lapierre et al., 2017. Overview on the current status of Zika virus pathogenesis and animal related research. J. Neuroimmune Pharmacol., (In Press).
    CrossRefDirect Link

  18. Dowd, K.A., C.R. DeMaso, R.S. Pelc, S.D. Speer and A.R.Y. Smith et al., 2016. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep., 16: 1485-1491.
    CrossRefDirect Link

  19. Dyer, O., 2016. Trials of Zika vaccine are set to begin in North America. BMJ., Vol. 353.
    CrossRefDirect Link

  20. Alera, M., L. Hermann, I.A. Tac-An, C. Klungthong and W. Rutvisuttinunt et al., 2015. Zika virus infection, Philippines, 2012. Emerg. Infect. Dis., 21: 722-724.
    CrossRefDirect Link

  21. Lanciotti, R.S., A.J. Lambert, M. Holodniy, S. Saavedra and L.D.C.C. Signor, 2016. Phylogeny of Zika virus in Western Hemisphere, 2015. Emerg. Infect. Dis., 22: 933-935.
    CrossRefDirect Link

  22. Wikan, N. and D.R. Smith, 2016. Zika virus: History of a newly emerging arbovirus. Lancet Infect. Dis., 16: e119-e126.
    CrossRefDirect Link

  23. Sumathy, K., B. Kulkarni, R.K. Gondu, S.K. Ponnuru and N. Bonguram, et al., 2017. Protective efficacy of Zika vaccine in AG129 mouse model. Scient. Rep., Vol. 7.
    CrossRefDirect Link

  24. Xie, X., Y. Yang, A.E. Muruato, J. Zou and C. Shan et al., 2017. Understanding Zika virus stability and developing a chimeric vaccine through functional analysis. mBio, Vol. 8.
    CrossRefDirect Link

  25. Dawe, B.E., C.A. Smalley, B.L. Tiner, D.W.C. Beasley and G.N. Milligan et al., 2016. Research and development of Zika virus vaccines. NPJ. Vaccines, Vol. 1.
    CrossRefDirect Link

  26. Guy, B., M. Saville and J. Lang, 2010. Development of sanofi pasteur tetravalent dengue vaccine. Hum. Vaccine, 6: 696-705.
    PubMedDirect Link

  27. Halstead, S.B. and S.J. Thomas, 2011. New Japanese encephalitis vaccines: Alternatives to production in mouse brain. Expert Rev. Vaccines, 10: 355-364.
    CrossRefPubMedDirect Link

  28. Chokephaibulkit, K., C. Sirivichayakul, U. Thisyakorn, A. Sabchareon and C. Pancharoen et al., 2010. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: Multicenter randomized controlled trial. Pediatr. Infect. Dis., 29: 1111-1117.
    CrossRefPubMedDirect Link

  29. Richner, J.M., S. Himansu, K.A. Dowd, S.L. Butler and V. Salazar et al., 2017. Modified mRNA vaccines protect against Zika virus infection. Cell, 168: 1114-1125.
    CrossRefPubMedDirect Link

  30. Pardi, N., M.J. Hogan, R.S. Pelc, H. Muramatsu and H. Andersen, et al., 2017. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 543: 448-451.
    CrossRefDirect Link

  31. Larocca, R.A., P. Abbink, J.P.S. Peron, P.M.D.A. Zanotto and M.J. Iampietro et al., 2016. Vaccine protection against Zika virus from Brazil. Nature, 536: 474-478.
    CrossRefDirect Link

  32. Dowd, K.A., S.Y. Ko, K.M. Morabito, E.S. Yang and R.S. Pelc et al., 2016. Rapid development of a DNA vaccine for Zika virus. Science, 354: 237-240.
    CrossRefPubMedDirect Link

  33. Abbink, P., R.A. Larocca, R.A. De La Barrera, C.A. Bricault and E.T. Moseley et al., 2016. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science, 353: 1129-1132.
    CrossRefPubMedDirect Link

  34. Hampton, T., 2016. DNA vaccine protects monkeys against Zika virus infection. JAMA., Vol. 316, No. 17.
    CrossRefDirect Link

  35. Stiasny, K., S. Kiermayr, H. Holzmann and F.X. Heinz, 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol., 80: 9557-9568.
    CrossRefPubMedDirect Link

  36. Dowd, K.A. and T.C. Pierson, 2011. Antibody-mediated neutralization of flaviviruses: A reductionist view. Virology, 411: 306-315.
    CrossRefDirect Link

  37. Kennedy, R.B., 2016. Pushing forward with Zika vaccines. EBioMedicine, 13: 29-30.
    CrossRefPubMedDirect Link

  38. Kim, E., G. Erdos, S. Huang, T. Kenniston, L.D. Falo Jr. and A. Gambotto, 2016. Preventative vaccines for Zika virus outbreak: Preliminary evaluation. EBioMedicine, 13: 315-320.
    CrossRefPubMedDirect Link

  39. Ioos, S., H.P. Mallet, I.L. Goffart, V. Gauthier, T. Cardoso and M. Herida, 2014. Current Zika virus epidemiology and recent epidemics. Med. Mal. Infect., 44: 302-307.
    CrossRefDirect Link

  40. Hajra, A., D. Bandyopadhyay, and S.K. Hajra, 2016. Zika virus: A Global threat to humanity: A comprehensive review and current developments. North Am. J. Med. Sci., 8: 123-128.
    CrossRefDirect Link

  41. Samarasekera, U. and M. Triunfol, 2016. Concern over Zika virus grips the world. Lancet, 387: 521-524.
    CrossRefPubMedDirect Link

  42. Betancourt, D., N.M.G.P. de Queiroz, T. Xia, J. Ahn and G.N. Barber, 2017. Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity. J. Immunol., 198: 3023-3038.
    CrossRefDirect Link

  43. Kostyuchenko, V.A., E.X.Y. Lim, S. Zhang, G. Fibriansah and T.S. Ng et al., 2016. Structure of the thermally stable Zika virus. Nature, 553: 425-428.
    CrossRefDirect Link

  44. Poland, G.A., I.G. Ovsyannikova, R.B. Kennedy, I.H. Haralambieva and R.M. Jacobson, 2011. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics, 15: 625-636.
    CrossRefPubMedDirect Link

  45. Mirza, M.U., S. Rafique, A. Ali, M. Munir and N. Ikram, et al., 2016. Erratum: Towards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins. Scient. Rep., Vol. 6.
    CrossRefDirect Link

  46. Veljkovic, V. and S. Paessler, 2016. Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection. F1000 Res., Vol. 5.
    CrossRefDirect Link

  47. Zhao, H., E. Fernandez, K.A. Dowd, S.D. Speer and D.J. Platt et al., 2016. Structural basis of Zika virus-specific antibody protection. Cell, 166: 1016-1027.
    CrossRefPubMedDirect Link

  48. Poland, G.A., R.B. Kennedy, B.A. McKinney, I.G. Ovsyannikova, N.D. Lambert, R.M. Jacobson and A.L. Oberg, 2013. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin. immunol., 25: 89-103.
    CrossRefPubMedDirect Link

  49. Kennedy, R.B. and G.A. Poland, 2011. The top five game changers in vaccinology: Toward rational and directed vaccine development. Omics, 15: 533-537.
    CrossRefPubMedDirect Link

  50. Bonin, C.R.B., G.C. Fernandes, R.W. dos Santos and M. Lobosco, 2017. Mathematical modeling based on ordinary differential equations: a promising approach to vaccinology. Hum. Vaccin. Immunother., 13: 484-489.
    CrossRefDirect Link

  51. Ashfaq, U.A. and B. Ahmed, 2016. De novo structural modeling and conserved epitopes prediction of zika virus envelop protein for vaccine development. Viral Immunol., 29: 436-443.
    CrossRefDirect Link

  52. Koff, W.C., D.R. Burton, P.R. Johnson, B.D. Walker and C.R. King et al., 2013. Accelerating next-generation vaccine development for global disease prevention. Science, Vol. 340, No. 6136.
    CrossRefDirect Link

  53. Singh, R.K., S.K. Badasara, K. Dhama and Y.P.S. Malik, 2015. Progress and prospects in vaccine research. Proceedings of the Chapter in National Workshop on Current Trends and Future Research Challenges in Vaccines and Adjuvants, November 19-20, 2015, ICAR Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India, pp: 1-19.

  54. Boigard, H., A. Alimova, G.R. Martin, A. Katz, P. Gottlieb and J.M. Galarza, 2017. Zika Virus-Like Particle (VLP) based vaccine. PLoS Negl. Trop. Dis., Vol. 11, No. 5.
    CrossRefDirect Link

  55. Barzon, L., M. Trevisan, A. Sinigaglia, E. Lavezzo and G. Palu, 2016. Zika virus: from pathogenesis to disease control. FEMS Microbiol. Lett., Vol. 363, No. 18.
    CrossRefDirect Link

  56. Pierson, T.C. and B.S. Graham, 2016. Zika virus: Immunity and vaccine development. Cell, 167: 625-631.
    CrossRefDirect Link

  57. Francis, Jr. T., 1953. Influenza: The new acquaintance. Ann. Int. Med., 39: 203-221.

  58. Halstead, S.B., S. Rojanasuphot and N. Sangkawibha, 1983. Original antigenic sin in dengue. Am. J. Trop. Med. Hyg., 32: 154-156.
    CrossRefDirect Link

  59. Mongkolsapaya, J., W. Dejnirattisai, X.N. Xu, S. Vasanawathana and N. Tangthawornchaikul et al., 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med., 9: 921-927.
    CrossRefPubMedDirect Link

  60. Screaton, G., J. Mongkolsapaya, S. Yacoub and C. Roberts, 2015. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol., 15: 745-759.
    CrossRefPubMedDirect Link

  61. Midgley, C.M., M. Bajwa-Joseph, S. Vasanawathana, W. Limpitikul and B. Wills et al., 2011. An in-depth analysis of original antigenic sin in dengue virus infection. J. Virol. 85: 410-421.
    CrossRefDirect Link

  62. Tsai, W.Y., A. Durbin, J.J. Tsai, S.C. Hsieh, S. Whitehead and W.K. Wang, 2015. Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J. Virol., 89: 7348-7362.
    CrossRefPubMedDirect Link

  63. Mizumoto, K., K. Ejima, T. Yamamoto and H. Nishiura, 2014. On the risk of severe dengue during secondary infection: A systematic review coupled with mathematical modeling. J. Vector Borne Dis., 51: 153-164.
    Direct Link

  64. Martins, K.A.O., J.M. Dye and S. Bavari, 2016. Considerations for the development of Zika virus vaccines. Vaccine, 34: 3711-3712.
    CrossRefDirect Link

  65. Flipse, J. and J.M. Smit, 2015. The complexity of a dengue vaccine: A review of the human antibody response. PLoS Negl. Trop. Dis., Vol. 9.
    CrossRefDirect Link

  66. Dejnirattisai, W., P. Supasa, W. Wongwiwat, A. Rouvinski and G. Barba-Spaeth et al., 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol., 17: 1102-1108.
    CrossRefDirect Link

  67. Beck, C., M.A. Jimenez-Clavero, A. Leblond, B. Durand and N. Nowotny et al., 2013. Flaviviruses in Europe: Complex circulation patterns and their consequences for the diagnosis and control of West Nile disease. Int. J. Environ. Res. Public Health, 10: 6049-6083.
    CrossRefDirect Link

  68. Paul, L.M., E.R. Carlin, M.M. Jenkins, A.L. Tan and C.M. Barcellona et al., 2016. Dengue virus antibodies enhance Zika virus infection. Clin. Transl. Immunol., Vol. 5.
    CrossRefDirect Link

  69. Guzman, M.G. and E. Harris, 2015. Dengue. Lancet, 385: 453-465.
    CrossRefDirect Link

  70. Schlothauer, T., S. Herter, C.F. Koller, S. Grau-Richards and V. Steinhart et al., 2016. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel., 29: 457-466.
    CrossRefPubMedDirect Link

  71. Johnson, B.W., O. Kosoy, D.A. Martin, A.J. Noga, B.J. Russell, A.A. Johnson and L.R. Petersen, 2005. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. Vector-Borne Zoonotic Dis., 5: 137-145.
    CrossRefDirect Link

  72. Izurieta, R.O., M. Macaluso, D.M. Watts, R.B. Tesh and B. Guerra et al., 2009. Anamnestic immune response to dengue and decreased severity of yellow fever. J. Global Infect. Dis., 1: 111-116.
    Direct Link

Keywords


  • Zika virus
  • zika fever
  • vaccines

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved